Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ethan Seah
Observed name:
ETHAN SEAH
Institution:
J Ints Bio (South Korea)
Observed institution:
J Ints Bio (South Korea)
ORCID:
0009-0008-7533-612X
Observed ORCID:
0009-0008-7533-612X
OpenAlex ID:
A5010440513
Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC).
2024
·
Sun Min Lim
, Byoung Chul Cho
, et al.
·
Journal of Clinical Oncology
·
7
PDF
JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC
2026
·
Eun Ji Lee
, Ji Ae Ko
, et al.
·
Clinical Cancer Research
·
6
PDF
PRPF4 Knockdown Suppresses Glioblastoma Progressionviathe p38 MAPK and ERK Signaling Pathways
2025
·
WANSOO KIM
, SONG PARK
, et al.
·
Anticancer Research
·
3
hMAGEA2Accelerates the Progression of Prostate Cancerviathe EFNA3–Erk1/2 Signaling Pathway
2024
·
SEHYEON HAN
, SOYOUNG JANG
, et al.
·
Anticancer Research
·
3
Veratramine Inhibits Human Non-Small Cell Lung Cancer Cell Growth by Inhibiting the Hedgehog Signaling Pathway
2025
·
Seoung-Woo Lee
, Hee-Yeon Kim
, et al.
·
Journal of pharmacopuncture
·
2
Dddr-30. Enhanced Chemo and Radio-sensitization of Gliomas by Hsp90 Inhibition With Jin-001, a Novel Blood-brain Barrier Penetrant Hsp90 Inhibitor
2024
·
Jihong Xu
, Harsha S Sugur
, et al.
·
Neuro-Oncology
·
2
PDF
Abstract CT184: Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI in EGFR mutated advanced/metastatic non-small cell lung cancer
2025
·
Sun Min Lim
, Byoung Chul Cho
, et al.
·
Cancer Research
·
1
Abstract CT154: Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC)
2024
·
Sun Min Lim
, Byoung Chul Cho
, et al.
·
Cancer Research
·
1
Abstract 4029: JIN-A04, highly effective tyrosine kinase inhibitor targeting HER2 exon 20 insertion mutations in NSCLC
2023
·
Mi Ra Yu
, Mi Ran Yun
, et al.
·
Cancer Research
·
1
EXTH-35 Role of HSP90 inhibition in modulating the glioblastoma tumor microenvironment
2026
·
Harsha Sugur
, Pratibha Sharma
, et al.
·
Neuro-Oncology
AI-driven virtual transcriptome screening to identify repurposable combination partners for JIN-A02 in NSCLC.
2026
·
Sangyeol Kim
, Anna Jo
, et al.
·
Journal of Clinical Oncology
Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI in EGFR-mutated advanced/metastatic non-small cell lung cancer.
2025
·
Sun Min Lim
, Byoung Chul Cho
, et al.
·
Journal of Clinical Oncology
Abstract 4234: Synergistic anti-proliferative effects of JIN-001, a novel HSP90 selective inhibitor, in combination with platinum-based drugs in ovarian cancer cell lines
2025
·
Jue Young Kim
, Ha-Yeon Shin
, et al.
·
Cancer Research
Exth-67. Preclinical Assessment of the Efficacy of Mpt0b640, an Orally Bioavailable Small Molecule Hsp90 Inhibitor, Against Gliomas
2022
·
Pratibha Sharma
, Jihong Xu
, et al.
·
Neuro-Oncology
PDF
Show more works
View as search
Works count:
14
Citation count:
26
H-index:
3
I10-index:
Year
Topic
Type